Mazdutide

Mazdutide is an acylated peptide described as a GLP-1 and glucagon receptor dual agonist.

Research overview

Mazdutide, also identified as IBI362 or LY3305677, is an acylated peptide. The cited class B1 receptor review describes it among ligands with activity at the GLP-1 and glucagon receptors. Its structural figure identifies a C20 diacid acyl group connected through a linker at K20. That literature description is retained separately from a complete sequence because the opened database representations could not be reconciled confidently [1].

The review explains a class B1 receptor recognition framework in which the peptide C-terminal region first engages an extracellular receptor domain, while the peptide N-terminal region engages the transmembrane pocket. It discusses G protein signalling, receptor trafficking and cAMP readouts. These are family-level mechanisms and comparative research measurements. The article also distinguishes available ligand-bound structures from compounds requiring further structural investigation; those broader receptor descriptions should not be presented as a directly solved mazdutide receptor complex [1].

A randomized phase 2 study of mazdutide was reported in adults at centres in China. The publication identifies the same dual-receptor research context, but a clinical study and a ligand-bound receptor structure represent different forms of evidence. Its presence in the reference list documents the reported study setting, while the review supplies the receptor framework. The unresolved identity values therefore remain explicit rather than being inferred from the existence of that study [2].

Laboratory storage and handling

Store sealed peptide vials under the temperature conditions stated in the lot documentation, protected from light and moisture. Let a cold vial reach room temperature before opening to limit condensation. Avoid repeated freezing and thawing of laboratory stocks, record storage history and the lot identifier, and use standard laboratory protective equipment. Chemical modifications and counterions should be checked against the supplied analytical description.

Questions about Mazdutide

References

1. Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease. Am J Physiol Endocrinol Metab 2024. PMID 38984948
2. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun 2023. PMID 38092790

Identity data checked on 2026-10-03. Literature summaries describe published research models and are not specifications of any product lot.